Maryland’s strength in the technology sector is making it one of the fastest-growing exporters of high-tech goods and services in the U.S.
Maryland ranks eighth on the list of the nation’s fastest-growing exporter of high tech goods, according to a recent report from Technology CEO Council, a public policy advocacy organization in Washington, D.C. More than 9.5 percent — or $24.425 billion — of the state’s GDP can be attributed to the tech sector.
Here I am presenting opportunities to those engaged in research for electric and other advanced vehicles, to engage in research related to their own research, earning some money for their efforts, as well as helping their country. Note: Some of these are restricted to American citizens, or certain “Permanent Resident” or “protected” foreigners. Others require watchful tracking of what the foreigners do.
The current DoD Small-Business Innovative Research (SBIR) Solicitation, 2014.2, will be open until June 25. There is a large selection of topics available. I will be selecting and rating many of these, to make it easier for readers to select topics of interest. This may take a week or so, because I first must visit the NY Auto Show and write a blog about it.
In our lead up to the 2014 USA Science and Engineering Festival, we at Lux are proud to present our second TouchCast interactive video. The video excerpt below comes from Forbes/Wolfe Emerging Technology Report’s recent full-length interview with Dr. Bahija Jallal, Executive Vice President of MedImmune, the global biologics research and development arm of AstraZeneca. Dr. Jallal shares with us a bit about MedImmune, her background, and the company’s partnership with the USA Science and Engineering Festival.
Maryland has a lot of technology interests, but Baltimore tech leader Jason Hardebeck thinks there’s room for one more: health IT.
Hardebeck, the former executive director of gb.tc, is heading up a new accelerator, DreamIt Health Baltimore. The accelerator is wrapping up its first cycle and Hardebeck thinks the program’s early success is a sign that health IT has a big future in Baltimore.
Principia Biopharma Inc., a South San Francisco-based developer of small molecule drugs within the fields of autoimmune disease and oncology, has raised $50 million in Series B funding. Sofinnova Ventures led the round, and was joined by return backers Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital. The company previously raised $40 million.www.principiabio.com
Maryland’s efforts to build out the local cybersecurity economy seem to be working. Cybersecurity startup Luminal recently announced a move to Maryland from West Virginia, and will be rewarded by a $600,000 investment from InvestMaryland, the state’s venture fund. With this investment, Luminal closed a total of $3.82 million in a Series A round of funding including Core Capital Partners and New Enterprise Associates.
As CivSource has reported Maryland has launched several initiatives aimed at growing the local cybersecurity economy, including tax incentives, investments and a research partnership leveraging local universities and the military. Maryland is building on its proximity to a number of critical defense assets and the federal government to attract new cybersecurity entrants. The state of Virginia is also working on a similar effort.
Cultural fit, bundling potential and a focus on work force optimization.
If your healthcare startup meets all or even two of these criteria, you’ll have a better than average chance of attracting attention from GE Healthcare.
Mike Swinford, President and CEO Global Services at GE Healthcare, explained the thinking behind three recent acquisitions as well as how the companies helped GE make more money.
Johns Hopkins University is among the 50 wealthiest universities across the globe.
The university’s endowment value in 2013 was $2.987 billion — good for 29th on the list of the wealthiest universities, according to higher education website nonprofitcollegesonline.com.
The pharmaceutical industry is regaining its swagger, as companies turn to big and sometimes daring deals to expand and reshape their operations.
On Tuesday alone, pharmaceutical companies announced $74 billion worth of potential deals, including an unorthodox $45.6 billion bid for Allergan, the maker of Botox, and a flurry of swaps and sales between Novartis of Switzerland and GlaxoSmithKline of Britain.
Noble Life Sciences (Gaithersburg, MD) and IBT Bioservices (Gaithersburg, MD) announce a newly optimized cotton rat model for preclinical studies of influenza therapies and vaccines. The companies jointly developed the model of influenza infection in the cotton rat.
Cotton rats are a vital tool to study influenza infection because adaptation of human influenza strains is not required for virus replication in the respiratory tract. Moreover, virus infection results in histopathological lesions in the lungs that are similar to those seen during natural infection of humans.
